Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.
about
Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophilsVenous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer AnticoagulantsPlatelets and their role in cancer evolution and immune systemPancreatic cancer and thromboembolic disease, 150 years after TrousseauInteraction between circulating cancer cells and platelets: clinical implicationAnticoagulants in cancerParaneoplastic thrombocytosis: the secrets of tumor self-promotionActivation of blood coagulation in cancer: implications for tumour progressionProgression and metastasis of lung cancerTrousseau's syndrome: multiple definitions and multiple mechanismsMicrovesicle-associated tissue factor and Trousseau's syndromeDifferential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.Elucidation of flow-mediated tumour cell-induced platelet aggregation using an ultrasound standing wave trap.Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy.Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.Multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome: case study.Protein glycosylation in cancer.Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome.Selectins facilitate carcinoma metastasis and heparin can prevent them.Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparinsA case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy.Pathobiological implications of mucin glycans in cancer: Sweet poison and novel targets.Thromboembolism in cancer patients: pathogenesis and treatment.Sialic acids in human health and disease.Androgen deprivation and thromboembolic events in men with prostate cancer.Glycan antagonists and inhibitors: a fount for drug discovery.Platelets and tumor cells: a new form of border control.The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis.Tissue factor-bearing microparticles and CA19.9: two players in pancreatic cancer-associated thrombosis?Coagulation, anticoagulation and pancreatic carcinoma.New insights into cancer-associated thrombosis.Trousseau's syndrome caused by bladder cancer producing granulocyte colony-stimulating factor and parathyroid hormone-related protein: A case report.Squamous cell carcinoma lung: Presented with bilateral lower limb deep venous thrombosis with gangrene formationHeparins attenuate cancer metastasis: are selectins the link?Altered tumor-cell glycosylation promotes metastasis.Paraneoplastic vasculitis and paraneoplastic vascular syndromes.Quality of life and supportive care for patients with metastatic renal cell carcinoma.Clinical models and biochemical predictors of VTE in lung cancer.Glycobiology of platelet-endothelial cell interactions.
P2860
Q24678441-B13F5B8F-22DA-4329-AE21-D8725DA2190CQ26741697-CCA36C14-0253-4A19-8051-A7374648140AQ26769754-C034EB2B-28BB-4A6A-96B3-443137DF4195Q26775634-D2E23420-09DC-4874-B5FD-F0126E34243DQ26778920-FF83DBCD-C899-491E-9A9A-EDB4C8A5844BQ26825228-E8662BA5-2FF7-4641-8DD7-4F68FDC87FA6Q26825427-A6C84829-8B31-4615-B544-851F9DEFD2C0Q26998742-8FA32456-FF69-40B6-92BE-7EB2E44E8C5DQ28066865-BB6E6856-82A5-4C09-A223-5DBA0AC076C7Q28301882-67012114-58FB-44B8-A7E1-61CE045480C7Q29026182-93227FDE-B815-4703-8706-6BBEFA73DF05Q30453962-3EF57072-C494-4FCC-ADAC-A212A2960628Q30468939-3E854207-FE7A-4367-A4A2-8D73AC9D2749Q33433520-A0672758-6A98-44F5-978F-E4EE659791C4Q35025682-9AEF7564-774C-4186-987C-D2B4FD069EEFQ35048404-5117002B-A3DE-4AF6-8CB2-5183550139CEQ35220883-BC811C61-2BF8-401A-A144-B46247E3F139Q35413473-A0D96AC8-475A-47C3-8AB8-FD702E3800E4Q35483514-118D0A27-FB36-48E2-ACBD-3179EA22F5FEQ35636253-3E22BF32-ED5A-47B6-8E15-05AA2161F596Q35810537-03A821C8-446D-43D1-9AC8-9FC031687081Q35849625-19F07209-7FEE-467C-9224-94E9FA7A9210Q36328299-6D999044-C1B1-43DE-9A78-62B292EB6A7FQ36588644-1B119E9A-B698-4D5B-B6D5-C7EF08910169Q36908164-9008963E-A1AF-4D08-8F2E-7F0F9E575292Q36919625-A134C504-7DC9-4029-B836-817589B278A9Q37027396-A1333885-2916-4FDD-9E60-675D780D1B20Q37095546-CEA1646D-7912-4CD5-886D-BD800785074AQ37129768-52D23091-6E89-4F14-A780-4C8E14DF0B5FQ37151056-CBA52218-A970-42B8-9D6E-928EA81EA4C8Q37204966-102D9C41-538E-44E7-A0A9-821049F9735DQ37307380-071266A5-CD2B-4F4D-8B8B-A8E4104C903DQ37407364-9EABD444-261F-4355-BF77-123BF5E885C3Q37422280-FA4076B3-591A-4D7F-8909-A23D7B59AB3DQ37500092-449EB355-D860-4146-B77E-1CCBAFA0CA7BQ37581540-26C50EA8-94BD-49B6-9AD1-6C7D2F1179CDQ37807497-54D02121-C0D3-4A6C-BA07-1B24237AF264Q38017587-A696D94D-B4F2-4D9F-80E2-45770512DA6BQ38205701-63D21CED-DD27-48EC-9D14-AA245394C76AQ38220163-4F37C664-B47B-4C1C-8B86-9D81B27515BE
P2860
Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Selectin-mucin interactions as ...... with mucinous adenocarcinomas.
@en
Selectin-mucin interactions as ...... with mucinous adenocarcinomas.
@nl
type
label
Selectin-mucin interactions as ...... with mucinous adenocarcinomas.
@en
Selectin-mucin interactions as ...... with mucinous adenocarcinomas.
@nl
prefLabel
Selectin-mucin interactions as ...... with mucinous adenocarcinomas.
@en
Selectin-mucin interactions as ...... with mucinous adenocarcinomas.
@nl
P2093
P2860
P356
P1476
Selectin-mucin interactions as ...... with mucinous adenocarcinomas.
@en
P2093
Ajit Varki
Mark Wahrenbrock
Nissi Varki
P2860
P304
P356
10.1172/JCI200318882
P407
P50
P577
2003-09-01T00:00:00Z